Abbott Laboratories (ABT) income statement
NYSE · Healthcare · Medical - Devices · 115,000 employees · CEO Robert Ford
- Price
- $106.20 +1.56%
- Market cap
- $184B
- Enterprise value
- $211B
- Last report
- Q3 '26 filed 2026-09-30
- Next report
- 2027-01-28 EPS est. $1.64
Abbott Laboratories (ABT) reported revenue of $13B for Q3 '26 (+14.5% year on year), operating income of $1.48B (11.3% of revenue) and net income of $920M. Over the last four quarters revenue was $48.2B.
Income statement
| Income statement | Trend | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.2B | $9.96B | $10.4B | $10.6B | $11B | $10.4B | $11.1B | $11.4B | $11.5B | $11.2B | $12.6B | $13B | |
| Cost of revenue | $4.98B | $4.94B | $5.07B | $5.21B | $5.38B | $4.91B | $4.85B | $5.03B | $4.92B | $4.88B | $5.29B | $5.59B | |
| Gross profit | $5.26B | $5.02B | $5.31B | $5.43B | $5.6B | $5.44B | $6.29B | $6.34B | $6.54B | $6.28B | $7.3B | $7.42B | |
| Research & development | $690M | $683M | $697M | $713M | $728M | $703M | $732M | $785M | $735M | $756M | $882M | $908M | |
| General & administrative | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $3.13B | $0 | $0 | $0 | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $0 | $411M | $420M | $422M | $422M | $658M | $841M | |
| Operating expenses | $3.39B | $3.64B | $3.62B | $3.61B | $3.61B | $3.76B | $4.24B | $4.31B | $4.29B | $4.44B | $5.52B | $5.95B | |
| Operating income | $1.86B | $1.39B | $1.69B | $1.82B | $1.99B | $1.69B | $2.05B | $2.06B | $2.25B | $1.84B | $1.78B | $1.48B | |
| Interest income | $89M | $80M | $82M | $91M | $91M | $82M | $71M | $77M | $78M | $106M | $0 | $0 | |
| Interest expense | $235M | $117M | $168M | $166M | $152M | $134M | $121M | $44M | $120M | $174M | $299M | $297M | |
| Other non-operating income (gains on investments, FX ...) | -$166M | -$168M | -$89M | -$288M | -$192M | -$224M | -$219M | -$244M | -$149M | $325M | $0 | $0 | |
| Total non-operating income | -$69M | $51M | -$79M | $122M | $40M | $90M | $98M | $123M | $107M | -$393M | -$258M | -$245M | |
| Income before tax | $1.8B | $1.44B | $1.61B | $1.94B | $2.03B | $1.78B | $2.15B | $2.18B | $2.36B | $1.45B | $1.52B | $1.23B | |
| Income tax | $201M | $211M | $305M | $294M | -$7.2B | $453M | $371M | $536M | $582M | $372M | $596M | $311M | |
| Net income | $1.59B | $1.23B | $1.3B | $1.65B | $9.23B | $1.33B | $1.78B | $1.64B | $1.78B | $1.08B | $928M | $920M | |
| EPS (basic) | $0.92 | $0.71 | $0.75 | $0.95 | $5.33 | $0.76 | $1.02 | $0.94 | $1.02 | $0.62 | $0.53 | $0.53 | |
| EPS (diluted) | $0.91 | $0.70 | $0.74 | $0.94 | $5.27 | $0.76 | $1.01 | $0.94 | $1.02 | $0.62 | $0.53 | $0.53 | |
| Shares (basic, weighted) | 1.73B | 1.73B | 1.73B | 1.73B | 1.73B | 1.75B | 1.74B | 1.75B | 1.75B | 1.75B | 1.74B | 1.74B | |
| Shares (diluted, weighted) | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.75B | 1.74B | 1.74B | |
| Depreciation & amortization | $813M | $805M | $805M | $801M | $807M | $756M | $777M | $791M | $792M | $730M | $1.01B | $0 | |
| EBITDA | $2.84B | $2.36B | $2.58B | $2.91B | $2.99B | $2.67B | $3.05B | $3.09B | $3.19B | $2.25B | $2.8B | $1.48B |
| Income statement | Trend | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.9B | $27.4B | $30.6B | $31.9B | $34.6B | $43.1B | $43.7B | $40.1B | $42B | $44.3B | |
| Cost of revenue | $9.61B | $14.3B | $14.8B | $15.2B | $17.2B | $19.9B | $21.3B | $20.1B | $20.6B | $19.7B | |
| Gross profit | $11.2B | $13.1B | $15.8B | $16.7B | $17.4B | $23.2B | $22.3B | $20B | $21.3B | $24.6B | |
| Research & development | $1.36B | $2.13B | $2.29B | $2.41B | $2.42B | $2.74B | $2.85B | $2.72B | $2.82B | $2.96B | |
| General & administrative | $6.67B | $9.12B | $9.74B | $0 | $0 | $0 | $0 | $0 | $0 | $12.4B | |
| Other operating expenses | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $1.25B | |
| Operating expenses | $8B | $11.1B | $12B | $12.1B | $12.1B | $14B | $14B | $13.6B | $14.5B | $16.6B | |
| Operating income | $3.25B | $1.97B | $3.84B | $4.59B | $5.29B | $9.2B | $8.36B | $6.44B | $6.83B | $8.05B | |
| Interest income | $99M | $124M | $105M | $94M | $46M | $43M | $183M | $385M | $344M | $230M | |
| Interest expense | $304M | $880M | $729M | $818M | $708M | $410M | $315M | $698M | $603M | $341M | |
| Other non-operating income (gains on investments, FX ...) | $1.53B | -$1.14B | $242M | -$304M | -$385M | $579M | -$259M | -$927M | -$765M | -$759M | |
| Total non-operating income | -$1.84B | $259M | -$971M | -$514M | -$323M | -$989M | -$56M | $229M | $188M | $418M | |
| Income before tax | $1.41B | $2.23B | $2.87B | $4.08B | $4.97B | $8.21B | $8.31B | $6.66B | $7.01B | $8.47B | |
| Income tax | $350M | $1.88B | $539M | $390M | $497M | $1.14B | $1.37B | $941M | -$6.39B | $1.94B | |
| Net income | $1.4B | $477M | $2.37B | $3.69B | $4.5B | $7.07B | $6.93B | $5.72B | $13.4B | $6.52B | |
| EPS (basic) | $0.95 | $0.27 | $1.35 | $2.07 | $2.52 | $3.97 | $3.94 | $3.30 | $7.67 | $3.74 | |
| EPS (diluted) | $0.94 | $0.27 | $1.34 | $2.06 | $2.50 | $3.94 | $3.91 | $3.27 | $7.64 | $3.72 | |
| Shares (basic, weighted) | 1.47B | 1.74B | 1.76B | 1.77B | 1.77B | 1.78B | 1.75B | 1.73B | 1.73B | 1.75B | |
| Shares (diluted, weighted) | 1.48B | 1.75B | 1.77B | 1.78B | 1.79B | 1.79B | 1.76B | 1.75B | 1.75B | 1.75B | |
| Depreciation & amortization | $1.35B | $3.02B | $3.28B | $3.01B | $3.33B | $3.54B | $3.27B | $3.24B | $3.22B | $3.12B | |
| EBITDA | $3.07B | $6.13B | $6.88B | $7.91B | $9B | $12.2B | $11.9B | $10.6B | $10.8B | $11.9B |
Standardised by Financial Modeling Prep from the company's filings; outflows and costs keep the sign the provider reports. Hover a period for its end date. Amounts in USD.
Revenue, operating income and growth
quarterlyMargins
quarterlyCosts as % of revenue
quarterlyThe other statements
Sources
Statements, segment revenue, metrics, estimates: Financial Modeling Prep. Segment profits and every reported line: SEC EDGAR (XBRL). Filings read: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30, 10-Q 2024-06-30
Data as of 2026-11-01